IgA Nephropathy Pipeline 2025: Groundbreaking Clinical Advancements by 30+ Global Leaders - DelveInsight | Featuring Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and

The market for IgA Nephropathy (IgAN) is being driven by several key factors. One of the primary drivers is the increasing prevalence and improved diagnosis of the disease, as greater awareness among healthcare professionals and advancements in diagnostic tools lead to earlier and more accurate detection. The significant unmet medical need further propels the market, as current treatment options are limited and many patients continue to progress to end-stage renal disease (ESRD), creating demand for more effective and targeted therapies. According to DelveInsight, the IgA Nephropathy pipeline comprises 30+ pharmaceutical and biotech companies actively developing 25+ therapeutic candidates targeting IgA Nephropathy. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "IgA Nephropathy Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving IgA Nephropathy Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of IgA Nephropathy Drug Development @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the IgA Nephropathy Pipeline Report

DelveInsight's IgA Nephropathy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
In April 2025, the FDA approved Vanrafia® (atrasentan), an endothelin A receptor antagonist developed by Novartis, marking a significant milestone in IgAN treatment. This approval was based on clinical data demonstrating its efficacy in reducing proteinuria, a key indicator of kidney function decline in IgAN patients.
In August 2024, Novartis received FDA accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor targeting the alternative complement pathway. This therapy has shown promise in reducing proteinuria in adults with primary IgAN at risk of rapid disease progression.
Key IgA Nephropathy companies such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals, and others are evaluating new drugs for IgA Nephropathy to improve the treatment landscape.
Promising IgA Nephropathy therapies include Atrasentan, SHR-2010, TAK-079, and others.

IgA Nephropathy Overview:

IgA nephropathy (IgAN), also known as Berger's disease, is the most prevalent primary glomerular disorder and can potentially progress to end-stage renal disease (ESRD). It is considered an autoimmune condition due to the interaction between galactose-deficient IgA1 (an intrinsic antigen) and circulating anti-glycan antibodies. IgA itself is a type of antibody produced by the immune system to defend against pathogens like bacteria and viruses.

The disease is most commonly seen in Caucasian and Asian males, typically emerging between the teenage years and late 30s, though it can develop at any age. While many cases stabilize or resolve over time, some individuals may experience disease progression, leading to ESRD within 20-25 years. In rare cases, rapid progression to kidney failure can occur within a few years if left untreated.

Symptoms can vary widely, from blood or protein in the urine to severe high blood pressure caused by kidney damage. The extent of tubulointerstitial injury in IgAN is strongly linked to how quickly kidney function declines and the patient's long-term renal prognosis. Since the underlying immune dysfunction persists, IgAN may recur even after kidney transplantation.

Download the IgA Nephropathy sample report to know in detail about the IgA Nephropathy treatment market @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

IgA Nephropathy Pipeline Analysis
The IgA Nephropathy pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the IgA Nephropathy Market.

Categorizes IgA Nephropathy therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging IgA Nephropathy drugs under development based on:

Stage of development

IgA Nephropathy Route of administration

Target receptor

Monotherapy vs. combination therapy

IgA Nephropathy Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

IgA Nephropathy Licensing agreements

Funding and investment activities supporting future IgA Nephropathy market advancement.

Unlock key insights into emerging IgA Nephropathy therapies and market strategies here: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

IgA Nephropathy Emerging Drugs

Atrasentan: Chinook Therapeutics
Atrasentan is a highly selective and potent endothelin A receptor (ETA) blocker that shows promise in treating various chronic kidney diseases by lowering proteinuria and exerting anti-inflammatory and anti-fibrotic effects to help preserve kidney function. Chinook chose IgA nephropathy (IgAN) as the primary target for atrasentan development because ETA activation plays a key role in promoting proteinuria, mesangial cell activation, kidney inflammation, and fibrosis-all critical drivers of IgAN progression. The drug is currently in Phase III clinical trials for the treatment of IgAN.

SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.

SHR-2010 is an investigational therapy under development for the treatment of Primary IgA Nephropathy. Developed by Guangdong Hengrui Pharmaceutical Co., Ltd., it is administered via injection and is currently in Phase II clinical trials. The drug targets the MASP-2 protein, with ongoing studies focused on assessing its effectiveness, safety profile, and pharmacokinetic properties in patients with Primary IgA Nephropathy.

TAK-079: Takeda
TAK-079, also known as mezagitamab, is designed to target and deplete CD38-expressing cells such as plasmablasts, plasma cells, and natural killer cells. Its use in IgA nephropathy is based on the premise that reducing the number of plasma cells producing abnormal IgA1 could help prevent the formation of harmful immune complexes and subsequent kidney damage. Currently, TAK-079 is being assessed in a Phase 1b clinical trial to determine its safety, tolerability, pharmacokinetics, and effectiveness in patients with primary IgA nephropathy who are on stable background treatment.

IgA Nephropathy Pipeline Therapeutic Assessment

IgA Nephropathy Assessment by Product Type
• Mono
• Combination
• Mono/Combination

IgA Nephropathy By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

IgA Nephropathy Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

IgA Nephropathy Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging IgA Nephropathy therapies and key IgA Nephropathy companies: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. IgA Nephropathy Current Treatment Patterns
4. IgA Nephropathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. IgA Nephropathy Late-Stage Products (Phase-III)
7. IgA Nephropathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. IgA Nephropathy Discontinued Products
13. IgA Nephropathy Product Profiles
14. IgA Nephropathy Key Companies
15. IgA Nephropathy Key Products
16. Dormant and Discontinued Products
17. IgA Nephropathy Unmet Needs
18. IgA Nephropathy Future Perspectives
19. IgA Nephropathy Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the IgA Nephropathy pipeline reports offerings: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.